Series A Tech Diligence Checklist: Check if Your Healthcare Product's Code Base 'Investable'?

You have a product that works. You have early traction. A hospital pilot is within reach, or a Series A term sheet is on the table. Then the investor sends over their technical diligence questionnaire and your stomach drops.

Suddenly, words like "audit trails," "encryption at rest," "penetration testing," and "SOC 2 readiness" are going all over the place for you! For starters, they are the difference between funding and a polite pass.

This is the exact situation hundreds of early-stage HealthTech founders walk into every year, and most of them are blindsided not because their product does not work, but because the codebase underneath it was never built to survive scrutiny.

This guide exists to fix that. If you are building in Telemedicine, Remote Patient Monitoring (RPM), Mental Health, or AI-assisted triage, and you are approaching a Series A or a hospital partnership conversation, here is exactly what technical diligence will examine and what "investable" actually means.

Let's first identify the core components of tech due diligence in healthcare for investors.

---

Why Technical Diligence in HealthTech Is Different

In a typical SaaS company, technical diligence covers things like system architecture, scalability, test coverage, and technical debt. All of that matters in HealthTech too.

But healthcare adds an entirely different layer of Regulatory compliance. And unlike scalability, which is a spectrum, compliance is binary. You either handle Protected Health Information (PHI) correctly or you do not.

According to the IBM Cost of a Data Breach Report 2024, the average cost of a healthcare data breach reached $9.77 million per incident, making healthcare the most expensive industry for breaches for the 14th consecutive year. Investors are well aware of such numbers and hospital procurement teams keep a close watch on these issues too. When they look at your codebase, they are not just evaluating software quality. They are assessing liability.

---

What Investors and Hospital Partners Actually Look At

Let us break this into five areas. Each one carries weight in a real diligence process.

1. HIPAA Compliance Infrastructure

This is the first question, and it is not theoretical. Diligence teams will want to see evidence, not just assurances.

What they check:

• Is PHI encrypted at rest and in transit using current standards (AES-256, TLS 1.2+)?
• Are audit logs in place that track every access to patient data?
• Is there a documented Business Associate Agreement (BAA) with every third-party vendor touching PHI, including your cloud provider, analytics tools, and communication platforms?
• Has a formal Security Risk Assessment (SRA) been conducted and documented?
• Is there a breach notification procedure that meets the 60-day reporting requirement?

The founder confusion: Many first-time HealthTech founders believe that using a HIPAA-compliant infrastructure provider (like AWS or Google Cloud) means their product is HIPAA compliant. It does not. Your cloud provider's compliance covers their infrastructure. Your application layer, your data handling logic, your access controls, your logging, those are your responsibility entirely.

A signed BAA with AWS is a starting point, not a finish line.

According to the U.S. Department of Health and Human Services (HHS) breach portal, over 89 million individuals were affected by healthcare data breaches in 2023 alone, with a significant proportion traced back to business associates, which include HealthTech vendors exactly like yours.

2. Data Architecture and PHI Handling

Beyond legal compliance, diligence reviewers want to see that PHI is treated as sensitive data at the architecture level, not just in your privacy policy.

What they check:

• Is PHI separated from application metadata in your database design?
• Do you apply role-based access control (RBAC) so that only the right roles can access patient records?
• Is PHI anonymized or pseudonymized in non-production environments (dev, staging, QA)?
• Are there any PHI leakage risks in logging, error messages, or third-party integrations?

The common failure point: Startups built quickly by generalist engineers frequently log too much. PHI ends up in application logs, error tracking tools like Sentry, and analytics dashboards where it has no business being. This is a red flag that signals the team does not think about data handling at the code level.

If your logs contain patient names, diagnosis codes, or any of the 18 HIPAA-defined PHI identifiers, your diligence review will surface it.

3. Security Posture

Investors writing Series A checks into HealthTech are typically funding companies that will eventually handle thousands or tens of thousands of patients. They want to know your security foundation can scale.

What they check:

• Has a penetration test been conducted by an independent third party?
• Are there automated vulnerability scans running regularly?
• Is multi-factor authentication (MFA) enforced for all system access, including internal admin tools?
• Is there network segmentation between patient data systems and other infrastructure?
• Are dependencies and third-party libraries monitored for known vulnerabilities (CVEs)?

Why this Matters Now?

The 2026 HIPAA Security Rule overhaul, expected to be finalized in May 2026 by the U.S. Department of Health and Human Services (HHS), is moving penetration testing and MFA from "addressable" recommendations to mandatory requirements. Investors who understand the regulatory trajectory are already expecting these controls at the Series A stage.

If your product fails a hospital security audit, that pilot is dead. And failed security audits are more common than founders expect, particularly when early code was written by generalist agencies without HealthTech experience.

4. Codebase Quality and Scalability

This is where traditional SaaS diligence and HealthTech diligence overlap. Reviewers want to see a codebase that a scaled engineering team can inherit and build on, not a pile of technical debt that will require a rewrite six months post-funding.

What they check:

• Is there documented test coverage, particularly around critical clinical workflows?
• Is the architecture modular enough to integrate with EHR systems (Epic, Cerner, Athenahealth) via FHIR/HL7 standards?
• Are there documented API contracts, both internal and external?
• Is there a clear separation between application logic and data access layers?
• How is the release process managed? Is there a CI/CD pipeline with automated checks?

The AI-specific concern: If your product includes AI-assisted features, such as triage algorithms, risk scoring, or clinical decision support, diligence will also examine your model validation documentation. Investors will ask: How was the model trained? On what data? Was it validated on a clinically representative population? Is there a feedback loop for monitoring model performance post-deployment?

According to a 2023 report by Accenture, 67% of healthcare executives cited data quality and integration challenges as their top barrier to scaling AI in clinical settings. If your AI feature cannot answer "what data was this trained on," that is a diligence failure.

5. Compliance Documentation and Operational Readiness

A technically sound product with no documentation is still a liability. Diligence reviewers, particularly those with institutional healthcare backgrounds, will expect to see that compliance is a process, not a one-time checkbox.

What they check:

• Is there a formal Privacy Policy and Terms of Service that accurately reflects your data practices?
• Are there documented incident response procedures?
• Is there a record of employee HIPAA training?
• Are BAAs with vendors current and on file?
• Is there a disaster recovery and business continuity plan?

What this signals to investors: Operational documentation tells a story about the team. Founders who have invested time in compliance documentation are signaling that they understand the healthcare market at a structural level. It is one of the clearest differentiators between a team that has done the work and one that built fast and hoped to fix compliance later.

---

Top 3 Common Ways HealthTech MVPs Fail Diligence

After reviewing dozens of early-stage HealthTech codebases, the failure patterns repeat with uncomfortable consistency.

Failure 1: Compliance was treated as a feature, not a foundation. The founders planned to "add HIPAA compliance" after achieving product-market fit. But compliance is not a feature you bolt on. It is an architectural decision that affects your database schema, your logging infrastructure, your vendor selection, and your deployment environment. Retrofitting compliance into a non-compliant codebase is expensive, time-consuming, and often requires rebuilding large parts of the system.

Failure 2: The development team had no HealthTech-specific experience. Generalist agencies can build functional software quickly. But healthcare software has domain-specific requirements that generalists consistently miss: PHI handling in error logs, audit trail completeness, BAA requirements for third-party tools, and FHIR-based interoperability patterns. The result is code that looks functional until it faces a hospital security audit or an investor's technical reviewer.

Failure 3: No independent security assessment was ever conducted. Many early-stage founders have never had their product reviewed by anyone outside their own team. In HealthTech, that is a significant gap. Penetration testing, even a lightweight external review, surfaces vulnerabilities that internal teams miss because they are too close to the codebase.

---

What "Investable" Actually Means

An investable HealthTech codebase is not a perfect one. Series A investors are not expecting enterprise-grade security from a 10-person company. What they are looking for is evidence of intentional architecture decisions: that the team built with compliance in mind from the start, that the security foundations are in place even if they need to mature, and that the technical leaders understand what they do not yet have and have a credible plan to get there.

The fastest path to "investable" is building compliance-first from day one, not as an afterthought. That means selecting a cloud architecture that supports HIPAA workloads, designing your data model with PHI boundaries built in, choosing third-party vendors who will sign BAAs, and writing code that treats patient data as the sensitive asset it legally is.

Founders who have done this work walk into diligence conversations with confidence. Those who have not spend those conversations making promises about what they will fix post-funding and hoping the investors do not probe too deep.

---

Your Pre-Diligence Checklist (Bonus)

Since you made this far in this detailed blog, here's a bonus easy-to-go checklist for you to make sure all the due diligence of your healthcare product are taken close care of. Before your next investor meeting or hospital procurement conversation happens, run through these:

---

Conclusion

Series A technical diligence in HealthTech is not a gotcha process. It is a structured evaluation of whether your product is ready for the scale and scrutiny that institutional capital and hospital partnerships bring. The founders who sail through it are not necessarily the ones with the most sophisticated technology. They are the ones who built with the right foundations from the beginning.

If your codebase has gaps, you have options. The critical mistake is walking into a diligence conversation without knowing where those gaps are. A pre-diligence technical audit, conducted before investor conversations begin, is the most efficient way to understand exactly where you stand and what you need to fix before the scrutiny arrives.

The healthcare market rewards builders who take compliance seriously. Your codebase should tell that story before you say a word.